Single-cell transcriptomic analysis reveals metastatic and immunosuppressive characteristics in meningioma brain-tumor interface

Abstract Background Meningioma is a common primary intracranial tumor with high recurrence and metastasis rate. Delineating the pathological ecosystem at the brain-tumor interface (BTI) of meningioma is critical for understanding the mechanisms of tumor metastasis and developing effective new therap...

Full description

Saved in:
Bibliographic Details
Main Authors: Boya Huang, Jinlian Liang, Xiaogen Tang, Yue Zhu, Lijuan Gao, Dongwei Fu, Cheng Wei, Yifang Li, Chao Ke, Hongyi Zhang, Oscar Junhong Luo
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Journal of Translational Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12967-025-06935-z
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Meningioma is a common primary intracranial tumor with high recurrence and metastasis rate. Delineating the pathological ecosystem at the brain-tumor interface (BTI) of meningioma is critical for understanding the mechanisms of tumor metastasis and developing effective new therapies. Methods To identify biomarkers of early metastasis and discover potential therapeutic targets, we integrated single-cell transcriptome datasets of meningioma, and identified the cell populations and molecular signatures uniquely present at the BTI. Results A specific BTI-enriched tumor cell population with a pro-EMT (epithelial mesenchymal transition) characteristics was associated with invasion and metastasis, and ANXA2 and COL5A1 were detected as the biomarkers for these BTI-enriched tumor cells. Additionally, we characterized the BTI-specific immunosuppressive microenvironment composed of SPP1 + tumor-associated macrophages, as well as specific endothelial cells (ACKR1 high) and pericytes (THY1 high) promoting the highly malignant invasive state of angiogenesis. Conclusions Collectively, BTI in meningioma is a metastatic and immunosuppressive zone. We have discovered potential biomarkers that help detect early metastasis and recurrence of meningioma.
ISSN:1479-5876